JPMorgan lowered the firm’s price target on Replimune Group to $38 from $42 and keeps an Overweight rating on the shares. The analyst updated models in the SMid cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REPL:
- Replimune Group put volume heavy and directionally bearish
- Replimune Group price target lowered to $48 from $50 at H.C. Wainwright
- Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
- Replimune Group presents updated data on RP2 in uveal melanoma
- Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
